Nasal glucagon is safe and effective in children and adolescents with type 1 diabetes: A real-world prospective cohort study
Anno:
2023
Tipologia prodotto:
Articolo in Rivista
Tipologia ANVUR:
Articolo su rivista
Lingua:
Inglese
Referee:
No
Nome rivista:
DIABETES, OBESITY AND METABOLISM
ISSN Rivista:
1462-8902
Intervallo pagine:
1-4
Parole chiave:
adolescents; children; hypoglycaemia; nasal glucagon; type 1 diabetes
Breve descrizione dei contenuti:
Nasal glucagon is now established as safe and effective for both adults and children with type 1 diabetes. Its market authorization has prompted widespread replacement of injected glucagon, but its uptake has been different in each country.
Id prodotto:
136440
Handle IRIS:
11562/1115128
ultima modifica:
20 febbraio 2024
Citazione bibliografica:
Zucchini, Stefano; Ripoli, Carlo; Cherubini, Valentino; Coccioli, Maria Susanna; Delvecchio, Maurizio; De Marco, Rosaria; Franceschi, Roberto; Gallo, Francesco; Graziani, Vanna; Iafusco, Dario; Innaurato, Stefania; Lasagni, Anna; Lombardo, Fortunato; Marigliano, Marco; Monti, Sara; Pascarella, Filomena; Pezzino, Giulia; Predieri, Barbara; Rabbone, Ivana; Schiaffini, Riccardo; Trada, Michela; Tumini, Stefano; Scaramuzza, Andrea,
Nasal glucagon is safe and effective in children and adolescents with type 1 diabetes: A real-world prospective cohort study«DIABETES, OBESITY AND METABOLISM»
, 2023
, pp. 1-4